IP Library Granted Patent US 7,981,439
Granted Patent B2
US 7,981,439 · App. 12/231,136 · Granted Jul 19, 2011

Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,981,439
App. No.
12/231,136
Granted
Jul 19, 2011
Kind
B2
Abstract

This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.

Claims (12)

1. A therapeutic pharmaceutical composition comprising:

a mixture including

(a) a water soluble drug susceptible to abuse;

(b) polyethylene oxide at about 3 to about 40 percent by weight;

(c) a disintegrant at about 2 to 25 percent by weight wherein the disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and

(d) sodium lauryl sulfate at about 1 to 10 percent by weight.

2. The therapeutic pharmaceutical composition of claim 1 , further comprising an emetic.

3. The therapeutic pharmaceutical composition of claim 2 , wherein the emetic is zinc sulfate.

4. The therapeutic pharmaceutical composition of claim 1 , wherein the polyethylene oxide has an average molecular weight ranging from 300,000 to about 5,000,000.

5. The therapeutic pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in unit dose form.

6. The therapeutic pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.

7. The therapeutic pharmaceutical composition of claim 1 , wherein the water soluble drug susceptible to abuse is present in an amount of 0.5 to about 25 percent by weight.

Assignments (8)
SECURITY INTEREST Recorded Jul 2, 2019
From: ACURA PHARMACEUTICALS, INC.
To: SCHUTTE, JOHN
Reel/Frame 049649/0950 →
SECURITY INTEREST Recorded Jul 2, 2019
From: SCHUTTE, JOHN
To: ABUSE DETERRENT PHARMACEUTICALS, LLC
Reel/Frame 049650/0104 →
RELEASE OF SECURITY INTEREST Recorded Oct 11, 2018
From: OXFORD FINANCE LLC
To: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICALS TECHNOLOGIES, INC.
Reel/Frame 047140/0800 →
SECURITY INTEREST Recorded Mar 17, 2017
From: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICAL TECHNOLOGIES, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 041623/0740 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY #14338143 PREVIOUSLY RECORDED ON REEL 033561 FRAME 0296. ASSIGNOR(S) HEREBY CONFIRMS THE LICENSE. Recorded Feb 25, 2016
From: ACURA PHARMACEUTICALS, INC
To: HIGHLAND PHARMACEUTICALS, LLC AND ITS AFFILIATES
Reel/Frame 038315/0279 →
LICENSE Recorded Aug 19, 2014
From: ACURA PHARMACEUTICALS, INC.; HIGHLAND PHARMACEUTICALS, LLC
To: HIGHLAND PHARMACEUTICALS, LLC
Reel/Frame 033561/0296 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2011
From: KUMAR, VIJAI; DIXON, DAVID; TEWARI, DIVYA; WADGAONKAR, DILIP B
To: HALSEY DRUG COMPANY, INC.
Reel/Frame 026380/0183 →
CHANGE OF NAME Recorded Jun 2, 2011
From: HALSEY DRUG CO., INC.
To: ACURA PHARMACEUTICALS, INC.
Reel/Frame 026382/0156 →